Eco Animal Health Group PLC Result of AGM
27 September 2024 - 11:21PM
RNS Regulatory News
RNS Number : 0770G
Eco Animal Health Group PLC
27 September 2024
27
September 2024
ECO Animal Health Group
plc
("ECO" or
the "Company")
Result of Annual General
Meeting
ECO Animal Health Group plc (AIM: EAH), a
rapidly growing global animal health company with a portfolio of
marketed veterinary products and a maturing proprietary R&D
pipeline, announces that at its Annual General Meeting held
yesterday all resolutions proposed to the meeting were duly
passed.
Votes received in relation to each resolution
were as follows:
|
Resolution
|
For
|
%
|
Discretionary
|
%
|
Against
|
%
|
|
01
|
41,070,268
|
100.00
|
Nil
|
0.00
|
Nil
|
0.000
|
|
02
|
36,456,852
|
88.768
|
Nil
|
0.00
|
4,613,165
|
11.232
|
|
03
|
40,961,390
|
99.735
|
Nil
|
0.00
|
108,878
|
0.265
|
|
04
|
34,395,129
|
84.081
|
Nil
|
0.00
|
6,511,866*
|
15.919
|
|
05
|
41,070,404
|
99.999
|
Nil
|
0.00
|
541
|
0.001
|
|
06
|
40,976,766
|
99.771
|
Nil
|
0.00
|
94,179
|
0.229
|
|
07
|
40,945,821
|
99.709
|
784
|
0.002
|
118,663
|
0.289
|
|
08
|
40,957,821
|
99.726
|
784
|
0.002
|
111,663
|
0.272
|
|
09
|
41,046,763
|
99.941
|
7,500
|
0.018
|
16,682
|
0.041
|
* Note: The Board has been informed that a
shareholder holding a block of 1,902,729 votes incorrectly lodged a
proxy in respect of these shares against resolution 4. This
shareholder acknowledged that the intent had been to vote
these shares in favour of resolution 4.
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global
offices including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a
proprietary, patented medication which is effective against both
respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGSEUFDWELSEFU
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Nov 2023 to Nov 2024
